Study to Evaluate the Safety and Efficacy of HLBLS-200 in Patients Requiring Hemostatic Technique

Inclusion Criteria: (during screening period) * Subject aged between 18 and 80 years old and scheduled for non-emergent hepatic resection. * Subject is willing to provide written consent and able to comply with study procedures. * Female subject of childbearing potential who is willing to use an adequate method of contraception or to be abstinent during the course of the study. Inclusion Criteria: (during hepatectomy) * Subjects who need to receive additional hemostatic treatment for blood oozing at the resection site after application of primary hemostatic methods. Exclusion Criteria: (during screening period) * Subject with a history of bleeding disorder, platelet disorder or bone marrow disorder. * Platelet count \< 50 X 10\^9/L or International normalized ratio \> 2. * Subject who received any drug affecting hemorrhage and/or hemostasis such as anticoagulants, antiplatelet agents or thrombolytic agent within 2 weeks prior to hepatectomy. * Subject with a history of hypersensitivity to the substance of the investigational device. * Creatinine clearance \< 30mL/min * Aspartate transaminase or alanine aminotransferase ≥ 3.0 X upper limit of normal. * Subject with a suspected disorder of decrease in fibrinolytic activity such as disseminated intravascular coagulation. * Subject with a history of alcohol or drug abuse. * Pregnant or lactating women * Subject who have participated in other clinical trial and have received investigation drugs or devices within 4 weeks prior to participation in the study. * Subject who were judged by the investigator as inadequate for participation in the study. Exclusion Criteria: (during hepatectomy) * Subject with following major bleeding (e.g. spurting hemorrhage, hemorrhage from hepatic veins) despite application of primary hemostatic methods * Subject who is deemed to need anticoagulant treatment within 48 hours of hepatectomy. * For other reason, subject who were judged by the investigator as inadequate for participation in the study.